Protein A Elution Buffer Excipients Prevent Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biopharmaceutical industry faces challenges in reducing protein aggregation during low pH steps in downstream processing of monoclonal antibodies, which can lead to reduced product yield and stability issues, particularly in Protein A affinity chromatography and viral inactivation processes.
Innovation Solution
The use of neutral excipients such as disaccharides, polyols, and poly(ethylene glycol) polymers in the elution buffer during Protein A affinity chromatography prevents protein aggregation and precipitation, enhancing product yield and stability during low pH treatment without interfering with viral inactivation, allowing for their safe presence in pharmaceutical preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low pH treatment is used for viral inactivation and protein elution, then viral inactivation is achieved and protein is eluted from the column, but protein aggregation and precipitation occur reducing product yield
Solution Approach 1:
A stabilizing excipient is introduced as an intermediary substance that mediates between the low pH treatment and the protein. The excipient protects the protein from aggregation and precipitation caused by low pH conditions during both elution and viral inactivation, while not interfering with the viral inactivation process itself. This allows the beneficial low pH treatment to proceed without the harmful side effect of protein aggregation.
Solution Approach 2:
The chemical environment parameters are changed by adding stabilizing excipients to the low pH buffer. This modifies the physical-chemical conditions during low pH treatment to prevent protein denaturation and aggregation, while maintaining the pH level necessary for viral inactivation. The excipient changes the protein's stability parameters without changing the pH parameter itself.
2Productivity
If stabilizing excipients are added to prevent protein aggregation, then product yield is improved, but the complexity of the elution buffer increases
Solution Approach 1:
Rather than changing the protein or the chromatography resin, the solution changes the buffer composition parameters by adding stabilizing excipients. These excipients are substances that are already commonly used in pharmaceutical formulations, so while they add to buffer complexity, they do not require entirely new materials or processes.
3Object-affected harmful factors
If low pH conditions are applied during Protein A chromatography, then viral inactivation is achieved, but soluble high molecular weight aggregates and insoluble precipitates form
Solution Approach 1:
The stabilizing excipient acts as a protective intermediary between the low pH conditions and the protein structure. It interferes with the aggregation process by occupying surfaces or forming protective complexes, preventing the protein from forming aggregates or precipitates under low pH stress, while allowing the low pH conditions to remain effective for viral inactivation.
Solution Approach 2:
The stabilizing excipient is added beforehand to the elution buffer to provide protective cushioning against the upcoming low pH stress. This pre-protection allows the protein to withstand the low pH conditions without aggregating, similar to how shock absorbers cushion against impact forces before they occur.
Data Source
AI summary
A method for purifying a target protein from a cell culture sample containing the target protein, viral compounds and other impurities, by affinity chromatography virus inactivation and optionally other purifications the affinity chromatography involvinga) loading an affinity chromatography column with the cell culture sample thereby binding the target protein to the affinity chromatography column;b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is disaccharides, polyols or poly (ethylene glycol) polymers;c) collecting one or more fractions containing the target protein obtained from (b);d) potentially combining the fractions obtained from (c) to form an elution product pool,and wherein the virus inactivation involvese) incubating the elution product pool at a pH from 2.5 to 4.5.